Teva (TEVA), Valeant (VRX) Deal Unlikely, BMO Analyst Tells Bloomberg

Teva Pharma (NYSE: TEVA) isn't interested in being acquired, BMO's David Maris told Bloomberg following meeting with management last week. Similarly, he doesn't think Valeant Pharma (NYSE: VRX) sees Teva as a good fit. Maris noted that Teva's bylaws say in must be domiciled as an Israeli company, and he isn't sure Valeant would want "disynergies."

Earlier shares of Teva gained on chatter a deal was in the works, but the rally was short-lived.

You May Also Be Interested In

• BHP Group (BHP) Said to Weigh Potential Takeover of Anglo American (NGLOY) - Bloomberg
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Micron Technology (MU) plans to construct a $100B "Megafab" employing more than 9,000 workers in Upstate NY - Nikkei